TRACON Pharmaceuticals (NASDAQ:TCON) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research note issued to investors on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a neutral rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.

TRACON Pharmaceuticals Stock Down 15.7 %

TCON stock opened at $0.18 on Wednesday. TRACON Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $14.75. The company has a market cap of $596,750.00, a price-to-earnings ratio of 0.26 and a beta of 1.35. The company has a 50 day moving average of $0.25 and a two-hundred day moving average of $2.07.

TRACON Pharmaceuticals (NASDAQ:TCON) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The business had revenue of $0.06 million for the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.